Using machine learning and a large volume of data on genes and existing drugs, researchers at Lund University in Sweden have identified a combination of statins and phenothiazines that is particularly promising in the treatment of the aggressive form of neuroblastoma. The results from experimental trials showed slowing of tumor growth and higher survival rates.

The childhood cancer, neuroblastoma, affects about 15–20 children in Sweden every year. Most of them fall ill before the age of 5. Neuroblastoma is characterized by, among other things, tumors that are often resistant to drug treatment, including chemotherapy. The disease exists in both mild and severe forms, and the Lund University researchers are mainly studying the aggressive form, high-risk neuroblastoma. This variant is the form of childhood cancer with the lowest survival rate.